Tirbanibulin: Effect in Actinic Keratosis
Tirbanibulin (trade name Klisyri) is a novel topical antiproliferative agent for the treatment of actinic keratosis on the face and scalp. The substance was approved in Europe in 2021 and represents an important expansion of dermatological treatment options for this common skin disease. In Germany, tirbanibulin is marketed as a 1 percent ointment in individual portion sachets and is used exclusively on medical prescription. The therapy lasts five days, which is comparatively short and thus an attractive option compared to older therapies such as 5 fluorouracil or imiquimod, which require significantly longer application periods.
Actinic keratosis is a precancerous skin lesion caused by UV radiation that can progress to squamous cell carcinoma if left untreated. Its frequency increases with age and cumulative UV exposure. Fair-skinned persons, persons with outdoor occupations, or those with immunosuppressive therapy are particularly affected. Tirbanibulin offers a short and study proven treatment option for mild to moderate findings on the face and scalp up to 25 cm² area.
Mechanism of Action
Tirbanibulin is a dual inhibitor of tubulin and Src tyrosine kinase. By binding to tubulin, the substance prevents the polymerization of microtubules, which are necessary for cell mitosis. In rapidly dividing cells such as actinic keratosis cells, the mitotic cycle is stopped and apoptosis occurs. The additional inhibition of Src tyrosine kinase, an important signaling molecule in tumorigenesis, enhances the antiproliferative effect.
The substance is selective for rapidly proliferating cells, so healthy, slowly dividing skin cells are relatively little affected. This selectivity is a major advantage over older topical therapies. Compared to 5 fluorouracil, the skin reaction is usually less pronounced, which improves compliance.
Pharmacokinetically, tirbanibulin is minimally absorbed systemically after topical application. Plasma concentrations are very low and result in no relevant systemic pharmacology. The main effect occurs locally in the treatment area. The short five day treatment period is sufficient to fully develop the antiproliferative effect in actinic keratosis lesions.
Indications
- Actinic keratosis grade I to II according to Olsen classification on the face and scalp in adults
- Treatment area up to 25 cm², approximately 5 times 5 cm
- Patients with extensive field cancerization in specific constellations, often as adjunctive therapy to cryotherapy or other procedures
Tirbanibulin is not suitable for application on mucous membranes, eyelids, near the eyes, on open wounds, or in heavily hyperkeratotic lesions. If invasive squamous cell carcinoma is suspected, biopsy and appropriate therapy are necessary.
Dosage and Administration
Adults: apply tirbanibulin 1 percent ointment once daily for five consecutive days to the treatment area. Application preferably in the morning, at approximately the same time of day.
Treatment area: up to a maximum of 25 cm² contiguous area on the face or scalp.
Application: wash hands thoroughly before and after application. Clean the treatment area and dry well. Apply the contents of one individual portion sachet with the finger evenly to the treatment area until the ointment disappears. Do not wash off, but allow it to absorb. Approximately 8 hours after application, the area can be washed with water.
Behavior after application: wash hands thoroughly after application. Avoid hand eye contact, as the substance is eye irritating. Do not wash, cover, or apply creams to the treatment area for 8 hours after application.
Assessment: clinical follow up examination after 8 weeks, if residual lesions are present, repeat therapy may be considered after individual evaluation.
Renal impairment / Hepatic impairment: no adjustment required due to minimal systemic absorption.
Adverse Effects
Very common: local skin reactions (LSR) in the treatment area, including erythema (redness), scaling, crust formation, swelling, erosions, or ulcerations. These reactions are expected and a sign of efficacy. Maximum approximately 8 days after start of therapy, resolving over approximately 2 weeks.
Common: pruritus, pain or burning at the application site, erysipelas like skin reaction, skin flaking.
Occasional: skin ulcerations, post inflammatory hyperpigmentation, temporary hypopigmentation.
Rare: severe allergic reactions, eye irritation upon accidental eye exposure, periorbital edema.
Note: local skin reactions are usually less pronounced and shorter lasting compared to 5 fluorouracil or imiquimod. The reaction is a sign of efficacy and not a reason to discontinue therapy as long as no serious complication exists.
Drug Interactions
- Other topical agents on the treatment area: during the 5 day treatment period and during resolution of local skin reactions, no other topical active substances or cosmetics should be applied to the area.
- Systemic medications: due to low systemic absorption, no relevant systemic interactions are known.
- UV radiation: protect the treatment area consistently from sun during and after therapy, as UV exposure can intensify the reaction and actinic keratosis represents pre existing UV damage.
- Other actinic keratosis therapies (cryotherapy, photodynamic therapy, 5 fluorouracil, imiquimod): staggered use in a structured treatment plan is possible.
Special Precautions
Pregnancy: not recommended due to limited data. If clinically necessary, strict risk benefit assessment. Breastfeeding: not recommended, consider alternative therapies.
Children: not approved for children, as actinic keratosis occurs practically exclusively in adults.
Contraindications: known hypersensitivity to tirbanibulin or excipients, application on mucous membranes, eyelids, near the eyes, or on open wounds.
Before application: detailed dermatological history and clinical assessment of skin lesions. Biopsy if invasive squamous cell carcinoma is suspected. Clinically document skin lesions, if necessary photographically.
During therapy: observe skin reactions, instruct patients on proper application and behavior. If severe complications such as infection or ulcerative reactions occur, pause therapy.
After therapy: follow up examination after 8 weeks, assessment of treatment success. Consistent UV protection with sun protection factor 50 or higher, wide brimmed hats, and avoidance of direct sun exposure. Regular skin cancer screening examinations.
Lifestyle: comprehensive UV protection, avoidance of tanning beds, regular dermatological screening in persons with UV risk profile.
Driving ability: not impaired by topical application.
You Might Also Be Interested In
- Imiquimod, topical immunomodulator for actinic keratosis
- Fluorouracil, topical cytostatic agent for actinic keratosis
- Diclofenac, topical NSAID for actinic keratosis
- Dithranol, other dermatological topical agent
- Methylaminolevulinat, photodynamic therapy for actinic keratosis
Frequently Asked Questions
How long does tirbanibulin therapy last?
The application period is only 5 consecutive days. This makes tirbanibulin significantly shorter than older topical therapies such as 5 fluorouracil (2 to 4 weeks) or imiquimod (4 to 6 weeks). After the 5 application days, there is approximately a 2 week phase with local skin reactions, followed by the healing phase. Assessment of treatment success occurs after 8 weeks.
Are skin reactions a good or bad sign?
Local skin reactions with redness, scaling, and crust formation are signs of the medication's efficacy. They indicate that actinic keratosis cells are being destroyed and the skin is renewing itself. Therefore, these reactions are desirable and should not lead to therapy discontinuation as long as they remain within the expected range. If reactions are very pronounced or painful or if signs of infection appear, consult a physician.
What is actinic keratosis and why is treatment important?
Actinic keratosis is a precancerous skin lesion caused by UV radiation. If left untreated, some of these lesions can progress to invasive squamous cell carcinoma. The probability per lesion per year is low, but the risk accumulates with multiple lesions and long term follow up. Treatment is therefore an important preventive measure, especially in extensive field cancerization.
Can I use tirbanibulin in summer?
Summer application is possible, however, consistent UV protection is especially important. During therapy and in the phase of skin reaction, the treatment area should be protected from direct sun. Fair skinned patients and persons with marked sun exposure should ideally plan therapy outside of peak sun intensity (late autumn, winter, early spring) if clinically appropriate.
Sources
- Gelbe Liste, Tirbanibulin Active Substance Profile
- BfArM, Federal Institute for Drugs and Medical Devices
- German Dermatological Society (DDG)
- AWMF S3 Guideline Actinic Keratosis and Squamous Cell Carcinoma
- European Medicines Agency, EPAR Klisyri
Legal Notice and Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or therapy recommendation. It does not replace the advice of a licensed physician or pharmacist. Tirbanibulin is a prescription medication and should be used under dermatological supervision, especially in cases of unclear differential diagnosis of skin lesions. All information is based on published expert information and recognized scientific sources at the time of preparation, with the manufacturer's current product information always being authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In a medical emergency, please call emergency number 112.